Cancer
Malignant Colon Neoplasm
CI-CAN-00007995Explore in graph →
Top-level225 active trials5 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007995Explore in graph →
Clinical trials
1,196 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (139)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT05983367 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | terminated | Phase 2 | 76 | Inspirna, Inc.INDUSTRY | 3 | Feb 20, 2026 |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | terminated | Phase 2 | 22 | Tempus AIINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03631641 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | terminated | Phase 2 | 3 | John HaysOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 92 | Gilead SciencesINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | terminated | Phase 2 | 10 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03524820 | Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer | terminated | Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01505166 | Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases(FANG-CLM) | terminated | Phase 2 | 3 | Gradalis, Inc.INDUSTRY | 1 | Nov 1, 2021 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT02402036 | A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer | terminated | Phase 2 | 10 | Georgetown UniversityOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02216149 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow(FluoHeart) | terminated | Phase 2 | 20 | Heikki JoensuuOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00845039 | A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab(FC-4) | terminated | Phase 2 | 4 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01729923 | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer(ADAPT) | terminated | Phase 2 | 27 | University of WashingtonOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | terminated | Phase 2 | 39 | Mayo ClinicOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00003485 | Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT00127036 | Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | terminated | Phase 2 | 65 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01322815 | A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI | terminated | Phase 2 | 11 | Georgetown UniversityOTHER | 1 | Aug 15, 2016 | clinicaltrials |
| NCT01320683 | Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT01111292 | Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2016 | clinicaltrials |
| NCT01339000 | Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2016 | clinicaltrials |
| NCT01186705 | Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer | terminated | Phase 2 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01149434 | Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | terminated | Phase 1 / Phase 2 | 19 | University of UtahOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01365910 | Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer | terminated | Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 26, 2014 | clinicaltrials |
| NCT01198548 | High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer | terminated | Phase 2 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT01344902 | An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon | terminated | Phase 1 / Phase 2 | 13 | PhotocureINDUSTRY | 1 | Oct 23, 2013 | clinicaltrials |
| NCT00002796 | Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00070265 | Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer | terminated | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00052585 | Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00677287 | Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer | terminated | Phase 1 / Phase 2 | 14 | Tokyo UniversityOTHER | 1 | Dec 29, 2009 | clinicaltrials |
| NCT00677612 | Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer | terminated | Phase 1 / Phase 2 | 14 | Tokyo UniversityOTHER | 1 | Dec 29, 2009 | clinicaltrials |
Data updated 22 days agoSource updated May 19, 2026source: clinicaltrials